Literature DB >> 10798824

Hair loss in psychopharmacology.

Y Mercke1, H Sheng, T Khan, S Lippmann.   

Abstract

Medication-induced alopecia is an occasional side effect of many psychopharmaceuticals. Most of the mood stabilizer and antidepressant drugs can lead to this condition. Some antipsychotic and antianxiety agents induce alopecia. Hair loss is also related to hypothyroidism, which can be induced by lithium and other agents. Alopecia might not be reported by some people, but physicians should be aware of this potential problem which may contribute to noncompliance. Lithium causes hair loss in 12-19% of long-term users. Valproic acid and/ or divalproex precipitates alopecia in up to 12% of patients in a dose-dependent relationship. Incidences up to 28% are observed with high valproate concentration exposures. These pharmaceuticals also can change hair color and structure. The occurrence of carbamazepine-induced alopecia is at or below 6%. Hair loss is less common with other mood stabilizers. Tricyclic antidepressants, maprotilene, trazodone, and virtually all the new generation of antidepressants may on rare occasions lead to alopecia. The same applies to haloperidol, olanzepine, risperidone, clonazepam, and buspirone, but not to other neuroleptics, benzodiazepines, or barbiturates, selected antihistamines, and antiparkinsonians. Discontinuation of the medication or dose reduction almost always leads to complete hair regrowth. The therapeutic value of mineral supplements remains unclear.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798824     DOI: 10.1023/a:1009074926921

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  15 in total

1.  Hair loss associated with long-term sertraline treatment in teenager.

Authors:  T Rais; Tanvir Singh; A Rais
Journal:  Psychiatry (Edgmont)       Date:  2005-07

Review 2.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 3.  The Use of Medicinal Plants for the Treatment of Alopecia in the Canon of Avicenna: An Evidence-Based Review.

Authors:  Zahra Boghrati; Sara Sabouri-Rad; Seyed Ahmad Emami; Mohsen Tahaghoghi Saber; Amirhossein Sahebkar; Zahra Tayarani-Najaran
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Buspirone: a possible cause of alopecia.

Authors:  Jason Faber; Randy A Sansone
Journal:  Innov Clin Neurosci       Date:  2013-01

5.  The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.

Authors:  Andrew Lloyd; Emma McIntosh; Martin Price
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Valproate as a mainstay of therapy for pediatric epilepsy.

Authors:  Renzo Guerrini
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database.

Authors:  Maria Tengstrand; Kristina Star; Eugène P van Puijenbroek; Richard Hill
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

Review 8.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Serum drug level-related sodium valproate-induced hair loss.

Authors:  Suresh K Ramakrishnappa; Mahesh N Belhekar
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

10.  Relevant issues in pharmacotherapy of psycho-cutaneous disorders.

Authors:  Sreyoshi Ghosh; Rishikesh V Behere; Psvn Sharma; S Savitha
Journal:  Indian J Dermatol       Date:  2013-01       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.